Published in Arch Neurol on July 11, 2011
Implications for Management of PET Amyloid Classification Technology (IMPACT) | NCT02778971
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol (2013) 9.43
Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol (2012) 2.84
Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol (2012) 2.65
Biomarker modeling of Alzheimer's disease. Neuron (2013) 2.51
Brain β-amyloid load approaches a plateau. Neurology (2013) 2.50
Amyloid-β assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology (2012) 2.26
Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques. JAMA Neurol (2015) 2.15
Apolipoprotein E, not fibrillar β-amyloid, reduces cerebral glucose metabolism in normal aging. J Neurosci (2012) 1.58
Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. J Nucl Med (2012) 1.55
Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically normal older individuals. Neurobiol Aging (2012) 1.43
Relationship of regional brain β-amyloid to gait speed. Neurology (2015) 1.43
Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study. Mol Psychiatry (2014) 1.42
Motion correction in simultaneous PET/MR brain imaging using sparsely sampled MR navigators: a clinically feasible tool. EJNMMI Phys (2015) 1.38
Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology (2012) 1.34
The role of apolipoprotein E (APOE) genotype in early mild cognitive impairment (E-MCI). Front Aging Neurosci (2013) 1.26
Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease. Neuroimage Clin (2013) 1.21
Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging (2012) 1.19
[18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease. Eur J Nucl Med Mol Imaging (2013) 1.19
Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications. Alzheimers Res Ther (2011) 1.07
Ushering in the study and treatment of preclinical Alzheimer disease. Nat Rev Neurol (2013) 1.03
Physical and structural basis for polymorphism in amyloid fibrils. Protein Sci (2014) 0.99
Amyloid polymorphism: structural basis and neurobiological relevance. Neuron (2015) 0.95
Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta. Adv Pharmacol (2012) 0.94
The receiver operational characteristic for binary classification with multiple indices and its application to the neuroimaging study of Alzheimer's disease. IEEE/ACM Trans Comput Biol Bioinform (2013) 0.94
Cerebral amyloid PET imaging in Alzheimer's disease. Acta Neuropathol (2013) 0.93
Molecular and cellular pathophysiology of preclinical Alzheimer's disease. Behav Brain Res (2016) 0.90
Amyloid-β positron emission tomography imaging probes: a critical review. J Alzheimers Dis (2013) 0.90
Regional amyloid deposition in amnestic mild cognitive impairment and Alzheimer's disease evaluated by [18F]AV-45 positron emission tomography in Chinese population. PLoS One (2013) 0.89
Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease. Neurobiol Aging (2013) 0.86
Should we disclose amyloid imaging results to cognitively normal individuals? Neurodegener Dis Manag (2013) 0.86
A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis. Biomed Res Int (2014) 0.85
Quantification of 18F-florbetapir PET: comparison of two analysis methods. Eur J Nucl Med Mol Imaging (2015) 0.85
Familiarity-based memory as an early cognitive marker of preclinical and prodromal AD. Neuropsychologia (2013) 0.85
Does posterior cingulate hypometabolism result from disconnection or local pathology across preclinical and clinical stages of Alzheimer's disease? Eur J Nucl Med Mol Imaging (2015) 0.84
Basal forebrain atrophy and cortical amyloid deposition in nondemented elderly subjects. Alzheimers Dement (2014) 0.84
Cerebral [(18) F]T807/AV1451 retention pattern in clinically probable CTE resembles pathognomonic distribution of CTE tauopathy. Transl Psychiatry (2016) 0.84
Amyloid and FDG-PET study of logopenic primary progressive aphasia: evidence for the existence of two subtypes. J Neurol (2015) 0.84
Brain amyloid-β burden is associated with disruption of intrinsic functional connectivity within the medial temporal lobe in cognitively normal elderly. J Neurosci (2015) 0.83
Active DNA Aβ42 vaccination as immunotherapy for Alzheimer disease. Transl Neurosci (2012) 0.83
Florbetapir positron emission tomography and cerebrospinal fluid biomarkers. Alzheimers Dement (2015) 0.83
Aβ Imaging: feasible, pertinent, and vital to progress in Alzheimer's disease. Eur J Nucl Med Mol Imaging (2012) 0.83
Cortical florbetapir-PET amyloid load in prodromal Alzheimer's disease patients. EJNMMI Res (2013) 0.83
Cognitive and functional patterns of nondemented subjects with equivocal visual amyloid PET findings. Eur J Nucl Med Mol Imaging (2015) 0.82
An N-heterocyclic amine chelate capable of antioxidant capacity and amyloid disaggregation. ACS Chem Neurosci (2012) 0.82
A consecutive case series experience with [18 F] florbetapir PET imaging in an urban dementia center: impact on quality of life, decision making, and disposition. Mol Neurodegener (2014) 0.82
PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders. BMC Neurol (2014) 0.82
A systematic review and meta-analysis of (18)F-labeled amyloid imaging in Alzheimer's disease. Alzheimers Dement (Amst) (2015) 0.81
Polymorphism of brain derived neurotrophic factor influences β amyloid load in cognitively intact apolipoprotein E ε4 carriers. Neuroimage Clin (2013) 0.81
Advances in our Understanding of the Pathophysiology, Detection and Management of Cerebral Amyloid Angiopathy. Eur Neurol Rev (2012) 0.81
Amyloid deposition and cognition in older adults: the effects of premorbid intellect. Arch Clin Neuropsychol (2013) 0.81
Mapping the effects of ApoE4, age and cognitive status on 18F-florbetapir PET measured regional cortical patterns of beta-amyloid density and growth. Neuroimage (2013) 0.81
Is in vivo amyloid distribution asymmetric in primary progressive aphasia? Ann Neurol (2016) 0.81
Cognitive Correlates of Basal Forebrain Atrophy and Associated Cortical Hypometabolism in Mild Cognitive Impairment. Cereb Cortex (2015) 0.80
The prognostic value of amyloid imaging. Eur J Nucl Med Mol Imaging (2012) 0.80
Amyloid-β imaging with PET in Alzheimer's disease: is it feasible with current radiotracers and technologies? Eur J Nucl Med Mol Imaging (2012) 0.79
Current status of biomarker research in neurology. EPMA J (2016) 0.79
Biomarkers for the clinical evaluation of the cognitively impaired elderly: amyloid is not enough. Imaging Med (2012) 0.79
Perspectives in molecular imaging using staging biomarkers and immunotherapies in Alzheimer's disease. ScientificWorldJournal (2013) 0.78
Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo. Eur J Nucl Med Mol Imaging (2013) 0.78
Biomarkers for the Early Detection and Progression of Alzheimer's Disease. Neurotherapeutics (2016) 0.78
Classification of amyloid status using machine learning with histograms of oriented 3D gradients. Neuroimage Clin (2016) 0.78
Pauses During Autobiographical Discourse Reflect Episodic Memory Processes in Early Alzheimer's Disease. J Alzheimers Dis (2015) 0.78
Alzheimer risk genes modulate the relationship between plasma apoE and cortical PiB binding. Neurol Genet (2015) 0.77
Brain amyloid in preclinical Alzheimer's disease is associated with increased driving risk. Alzheimers Dement (Amst) (2016) 0.77
FIBT versus florbetaben and PiB: a preclinical comparison study with amyloid-PET in transgenic mice. EJNMMI Res (2015) 0.77
Imaging Brain Metabolism and Pathology in Alzheimer's Disease with Positron Emission Tomography. J Alzheimers Dis Parkinsonism (2014) 0.77
Amyloid- and FDG-PET imaging in amyotrophic lateral sclerosis. Eur J Nucl Med Mol Imaging (2016) 0.76
Amyloid imaging: liberal or conservative? Let the data decide. Arch Neurol (2011) 0.76
The effect of 18F-florbetapir dose reduction on region-based classification of cortical amyloid deposition. Eur J Nucl Med Mol Imaging (2014) 0.76
Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care. Alzheimers Dement (Amst) (2016) 0.76
Recent advances in neuroimaging biomarkers in geriatric psychiatry. Curr Psychiatry Rep (2013) 0.76
PRECISION MEDICINE - The Golden Gate for Detection, Treatment and Prevention of Alzheimer's Disease. J Prev Alzheimers Dis (2016) 0.75
Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging. Eur J Nucl Med Mol Imaging (2015) 0.75
Amyloid imaging in depression: a predictor of Alzheimer's disease? Eur J Nucl Med Mol Imaging (2014) 0.75
Cortical β-amyloid levels and neurocognitive performance after cardiac surgery. BMJ Open (2013) 0.75
Biomarkers for Early Diagnostic of Mild Cognitive Impairment in Type-2 Diabetes Patients: A Multicentre, Retrospective, Nested Case-Control Study. EBioMedicine (2016) 0.75
Quantitative multimodal multiparametric imaging in Alzheimer's disease. Brain Inform (2016) 0.75
Degradation in intrinsic connectivity networks across the Alzheimer's disease spectrum. Alzheimers Dement (Amst) (2016) 0.75
Optimizing Effect Sizes With Imaging Enrichment and Outcome Choices for Mild Alzheimer Disease Clinical Trials. Alzheimer Dis Assoc Disord (2016) 0.75
Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database. Alzheimers Res Ther (2017) 0.75
Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment. J Alzheimers Dis (2017) 0.75
Influence of APOE Genotype on Alzheimer's Disease CSF Biomarkers in a Spanish Population. Biomed Res Int (2016) 0.75
Association between Cerebral Amyloid Deposition and Clinical Factors Including Cognitive Function in Geriatric Depression: Pilot Study Using Amyloid Positron Emission Tomography. Clin Psychopharmacol Neurosci (2016) 0.75
Effect of apolipoprotein E phenotype on the association of plasma amyloid β and amyloid positron emission tomography imaging in Japan. Alzheimers Dement (Amst) (2017) 0.75
PET-Florbetapir findings in primary cerebral amyloidoma. J Neurol (2015) 0.75
Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science (2006) 27.96
Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement (2011) 24.02
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol (2009) 14.42
Molecular, structural, and functional characterization of Alzheimer's disease: evidence for a relationship between default activity, amyloid, and memory. J Neurosci (2005) 12.85
Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability, and relation to Alzheimer's disease. J Neurosci (2009) 12.05
A survey of genetic human cortical gene expression. Nat Genet (2007) 12.04
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab (2007) 11.79
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans. Ann Neurol (2006) 11.23
Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol (2007) 10.75
Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet (2011) 10.07
A high-density whole-genome association study reveals that APOE is the major susceptibility gene for sporadic late-onset Alzheimer's disease. J Clin Psychiatry (2007) 7.23
Amyloid deposition is associated with impaired default network function in older persons without dementia. Neuron (2009) 7.02
Brain work and brain imaging. Annu Rev Neurosci (2006) 6.99
Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA (2011) 6.92
Functional brain abnormalities in young adults at genetic risk for late-onset Alzheimer's dementia. Proc Natl Acad Sci U S A (2003) 6.46
APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol (2010) 6.17
Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 5.55
Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet (2010) 5.52
Frontotemporal dementia: clinicopathological correlations. Ann Neurol (2006) 5.14
Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease. Arch Neurol (2009) 4.55
Disruption of functional connectivity in clinically normal older adults harboring amyloid burden. J Neurosci (2009) 4.50
Exercise and pharmacotherapy in the treatment of major depressive disorder. Psychosom Med (2007) 4.49
Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med (2009) 4.45
The default mode network and self-referential processes in depression. Proc Natl Acad Sci U S A (2009) 4.05
Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics. Nat Rev Drug Discov (2007) 4.03
Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging (2009) 3.97
Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci (2007) 3.91
Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report. Arch Neurol (2007) 3.83
Amyloid plaques disrupt resting state default mode network connectivity in cognitively normal elderly. Biol Psychiatry (2009) 3.72
Identification of the genetic basis for complex disorders by use of pooling-based genomewide single-nucleotide-polymorphism association studies. Am J Hum Genet (2006) 3.67
Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol (2012) 3.66
Cognition, reserve, and amyloid deposition in normal aging. Ann Neurol (2010) 3.64
Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. Arch Neurol (2009) 3.60
Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease. Neurology (2012) 3.58
Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol (2007) 3.55
Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 E280A kindred: a case-control study. Lancet Neurol (2012) 3.48
Resting-state functional MRI in depression unmasks increased connectivity between networks via the dorsal nexus. Proc Natl Acad Sci U S A (2010) 3.42
Genetic control of human brain transcript expression in Alzheimer disease. Am J Hum Genet (2009) 3.35
Common Kibra alleles are associated with human memory performance. Science (2006) 3.30
The Alzheimer's Disease Neuroimaging Initiative positron emission tomography core. Alzheimers Dement (2010) 3.30
Regional aerobic glycolysis in the human brain. Proc Natl Acad Sci U S A (2010) 3.25
Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. Am J Psychiatry (2002) 3.20
Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. J Am Coll Cardiol (2012) 3.19
Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol (2005) 3.09
Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A (2005) 3.02
APOE4 allele disrupts resting state fMRI connectivity in the absence of amyloid plaques or decreased CSF Aβ42. J Neurosci (2010) 2.99
Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol (2008) 2.96
FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. Brain (2007) 2.96
Brain abnormalities in human obesity: a voxel-based morphometric study. Neuroimage (2006) 2.94
Treatment course with antidepressant therapy in late-life depression. Am J Psychiatry (2012) 2.94
Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med (2008) 2.92
Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol (2010) 2.91
Cerebrospinal fluid tau and ptau(181) increase with cortical amyloid deposition in cognitively normal individuals: implications for future clinical trials of Alzheimer's disease. EMBO Mol Med (2009) 2.87
The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis Assoc Disord (2006) 2.86
Amyloid deposition, hypometabolism, and longitudinal cognitive decline. Ann Neurol (2012) 2.84
Spatial correlation between brain aerobic glycolysis and amyloid-β (Aβ ) deposition. Proc Natl Acad Sci U S A (2010) 2.80
Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Neuroimage (2009) 2.80
Alzheimer's Prevention Initiative: a plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis (2011) 2.78
Functional alterations in memory networks in early Alzheimer's disease. Neuromolecular Med (2010) 2.77
Phenotypic variability associated with progranulin haploinsufficiency in patients with the common 1477C-->T (Arg493X) mutation: an international initiative. Lancet Neurol (2007) 2.72
In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J Nucl Med (2010) 2.72
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects. Alzheimers Dement (2010) 2.68
Functional links between Aβ toxicity, endocytic trafficking, and Alzheimer's disease risk factors in yeast. Science (2011) 2.66
Florbetapir PET analysis of amyloid-β deposition in the presenilin 1 E280A autosomal dominant Alzheimer's disease kindred: a cross-sectional study. Lancet Neurol (2012) 2.65
Alzheimer disease and cognitive reserve: variation of education effect with carbon 11-labeled Pittsburgh Compound B uptake. Arch Neurol (2008) 2.62
Altered emotional interference processing in affective and cognitive-control brain circuitry in major depression. Biol Psychiatry (2007) 2.61
Alzheimer's disease is associated with reduced expression of energy metabolism genes in posterior cingulate neurons. Proc Natl Acad Sci U S A (2008) 2.59
Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch Neurol (2002) 2.58
Amyloid-β associated cortical thinning in clinically normal elderly. Ann Neurol (2011) 2.57
Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet (2010) 2.51
The A4 study: stopping AD before symptoms begin? Sci Transl Med (2014) 2.43
Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report. Arch Neurol (2009) 2.42
Enrichment of C-terminal fragments in TAR DNA-binding protein-43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol (2008) 2.41
Brain volume decline in aging: evidence for a relation between socioeconomic status, preclinical Alzheimer disease, and reserve. Arch Neurol (2008) 2.40
Metabolomics in early Alzheimer's disease: identification of altered plasma sphingolipidome using shotgun lipidomics. PLoS One (2011) 2.30